BRIEF-Prelude Therapeutics Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib

Reuters
11 Dec 2024
BRIEF-Prelude <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib

Dec 11 (Reuters) - Prelude Therapeutics PRLD.O:

  • PRELUDE THERAPEUTICS PRESENTS PRELIMINARY RESULTS OF PHASE 1 DOSE-ESCALATION STUDY OF PRT2527 AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

  • PRELUDE THERAPEUTICS INC: PLANS TO SEEK A PARTNER FOR FUTURE DEVELOPMENT OF PRT2527 IN HEMATOLOGIC MALIGNANCIES

Source text: ID:nGNX2ZxGNs

Further company coverage: PRLD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10